Thrombomodulin is an endothelial cell membrane protein that is a cofactor required for the rapid activation of plasma protein C. We now report that plasma and urine of normal subjects contains a modified form of thrombomodulin that is soluble. The levels measured by radioimmunoassay were 292±60 ng thrombomodulin/ml plasma and 102±38 ng thrombomodulin/ml urine. Thrombomodulin was isolated from both plasma and urine by immunoaffinity chromatography using a polyclonal anti-human thrombomodulin IgG column. The 
Introduction
Protein C is a vitamin K-dependent glycoprotein of 62,000 mol wt, which circulates in human plasma at a concentration of -4 ,ug/ml (1) . Protein C is converted to a protease with anticoagulant function by thrombin. The conversion requires an endothelial cell membrane protein cofactor, thrombomodulin, which was first isolated from rabbit lung (2) . We have isolated the human form of thrombomodulin from placenta (3) and lung (4) and have prepared both polyclonal (3) and monoclonal (5) Receivedfor publication 22 July 1985. brain (6, 7) . The greatest content of thrombomodulin is in lung and placenta as measured by radioimmunoassay of extracts of these tissues (7) . We now report that human plasma and urine contain a soluble form of thrombomodulin that has been detected by both radioimmunoassay and by a functional assay.
Methods
Except where indicated, all reagents were from Sigma Chemical Co., St. Louis, MO. Protein C (8) , thrombin (9) , and antithrombin III (10) were isolated from human plasma. Human thrombomodulin was isolated from placenta as previously reported (3). Polyclonal anti-human thrombomodulin antibody (3) and mouse monoclonal anti-thrombomodulin antibody (5) were prepared using placental thrombomodulin as the antigen (3) . Incubation was continued for an additional 1 h at room temperature. The S. aureus organisms were collected by centrifugation at 14,000 g for 10 min, the supernatant was removed, and the 1251I-thrombomodulin bound was measured in a gamma scintillation spectrometer.
Cofactor activity ofthrombomodulin. Reaction mixtures contained the following: 0.5 gM protein C, 40 nM thrombin, and a sample in a total vol of 30 pA containing 20 mM Tris, pH 7.4, 0.15 M NaCI, 1 mM CaC12, and 5 mg bovine serum albumin/ml. Protein Ca formed was measured as described previously (3) .
Immunoblot ofthrombomodulin. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed by the method of Laemmli (12) using 4% acrylamide in the stacking and 10% acrylamide in the running gel. Samples of thrombomodulin from urine, and plasma were electrophoresed with and without 2-mercaptoethanol. Immunoblotting was performed by the method of Burnette (13) . The thrombomodulin was detected by two methods. In one method, polyclonal anti-thrombomodulin serum was used at a 1:250 dilution and detection was made using '251I-protein A and autoradiography. The other method used '251-monoclonal anti-thrombomodulin IgG for direct detection ofthrombomodulin.
Results
Properties ofplasma and urine thrombomodulin. In preliminary studies we assayed samples of human urine and plasma for thrombomodulin antigen as described below. In these experiments we consistently detected thrombomodulin antigen in both fluids even though we could not detect thrombomodulin activity by protein C-activating cofactor assay ofthe fluids. To definitively establish that thrombomodulin was actually contained in both plasma and urine, we performed immunoaffinity chromatography as described in methods. The eluates of both plasma and urine were found to have protein C-activating cofactor activity that was linear with time and completely dependent on both protein C and thrombin. The protein C dependence of urine thrombomodulin is shown in Fig. 1 . Similar results were obtained using thrombomodulin isolated from plasma. The apparent Mi- Radioimmunoassay ofplasma and urine thrombomodulin. A standard curve ofthe radioimmunoassay ofthrombomodulin using isolated placental thrombomodulin is shown in Fig. 6 . Assays of urine, plasma, and affinity-purified materials from both sources are also shown and all appear to have similar slopes. We also added known amounts of placental thrombomodulin to both plasma and urine, and showed that there was good recovery of the added material, further indicating that thrombomodulin is accurately measured. We determined the content of thrombomodulin in the urine and plasma of normal subjects as shown in Table I . We have also measured thrombomodulin antigen in serum and find levels identical to those in plasma. In order to exclude the possibility that soluble thrombomodulin was not truly soluble but was contained in fragments of membrane, we subjected serum to ultracentrifugation at 150,000 g for I h and carried out a radioimmunoassay of the supernatant fraction. All of the thrombomodulin antigen remained in the supernatant, indicating that the material is actually soluble. (14) . If the average content of thrombomodulin is 40,000 molecules/cell as we find on cultured umbilical vein endothelial cells (5), then the total content ofthrombomodulin in endothelium is -300 mg. Circulating thrombomodulin would total -0.8 mg (0.3 ,g/ml X 2600 ml plasma).
Thus the proteolysis of a small fraction of cellular thrombomodulin could conceivably account for the circulating form. We cannot estimate this fraction since the plasma circulation time of soluble thrombomodulin is unknown. We also do not know the source of urinary thrombomodulin. It appears essentially identical to plasma thrombomodulin by immunoblotting, suggesting that it is probably derived from plasma. We also do not know why we are unable to measure directly thrombomodulin activity by protein C activation assay in plasma. The material isolated from plasma by immunoaffinity chromatography is nearly fully active; however, the yield of material purified from plasma is only 2-5%. The low yield could result from the very small amount of protein involved, which may be lost during chromatography or the subsequent dialysis after elution from the affinity column to remove NaSCN. Alternatively, it may be that most of the immunoassayed thrombomodulin in plasma is degraded to inactive forms that do not bind sufficiently tightly to the affinity column to be recovered upon purification. Furthermore, it is difficult to measure protein C activation directly in plasma since antithrombin III inhibits thrombin relatively rapidly.
The finding that thrombomodulin exists in a form that is both soluble and functionally active has potential therapeutic implications. Thus, if the structure of soluble thrombomodulin can be determined, it may be possible to produce large amounts of this moiety by molecular cloning techniques. Such a protein could be used as a natural anticoagulant that could inhibit thrombus formation in pathological states.
